Musculoskeletal complaints are exceedingly common (71.5%) in those receiving long-term (6 months or longer) aromatase inhibitor therapy.

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.